

Online supplemental material

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590

Takashi Kojima^a, Hiroki Hara^b, Akihito Tsuji^c, Hisateru Yasui^d, Kei Muro^e, Taroh Satoh^f, Takashi Ogata^g, Ryu Ishihara^h, Masahiro Gotoⁱ, Hideo Baba^j, Tomohiro Nishina^k, Shirong Han^l, Tomoko Sakata^l, Naoyoshi Yatsuzuka^l, Toshihiko Doi^m, Ken Katoⁿ


^aDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan; ^bDepartment of Gastroenterology, Saitama Cancer Center, Saitama, Japan; ^cDepartment of Medical Oncology, Kagawa University Hospital, Kagawa, Japan; ^dDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Hyogo, Japan; ^eDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan; ^fDepartment of Frontier Science for Cancer and Chemotherapy, Osaka University Hospital, Osaka, Japan; ^gDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan; ^hDepartment of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan; ⁱDivision of Medicine, Osaka Medical College Hospital, Osaka, Japan; ^jDepartment of Gastroenterological Surgery, Kumamoto University Hospital, Kumamoto, Japan; ^kDepartment of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan; ^lDepartment of Medical Oncology, MSD K.K., Tokyo, Japan; ^mDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan; ⁿDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

Esophagus

Corresponding Author

Ken Kato, MD, PhD
National Cancer Center Hospital
5-1-1, Tsukiji, Chuo-ku
Tokyo, 104-0045, Japan
Phone: 03-3542-2511 (7902)
Fax: 03-3452-3815
Email: kenkato@ncc.go.jp

Online Resource 1. CONSORT diagram.



Online Resource 2. Subsequent therapy in the Japanese population

Therapy, n (%)	Pembrolizumab + chemotherapy <i>n</i> = 64 ^a	Chemotherapy <i>n</i> = 65 ^a
All patients	44 (68.8)	49 (75.4)
Incidence ≥5% in any treatment group		
Cisplatin	11 (17.2)	12 (18.4)
Docetaxel	5 (7.8)	8 (12.3)
Fluorouracil	20 (31.3)	14 (21.5)
Oxaliplatin	10 (15.6)	2 (3.1)
Paclitaxel	31 (48.4)	36 (55.4)
Ramucirumab	5 (7.8)	4 (6.2)
Immunotherapy incidence ≥0%		
Anti-LAG-3 mAb	0 (0)	1 (1.5)
Anti-PD-1 mAb	0 (0)	1 (1.5)
Nivolumab	5 (7.8)	11 (16.9)
Pembrolizumab	2 (3.1)	0 (0)

^aNumber of patients who discontinued study medication.